Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary

A report of six cases

Masashi Takano, Yoshihiro Kikuchi, Kazuya Kudoh, Tomoko Goto, Kenichi Furuya, Ryoko Kikuchi, Tsunekazu Kita, Keiichi Fujiwara, Tanri Shiozawa, Daisuke Aoki

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Clear cell carcinoma (CCC) of the ovary is well-known to be chemotherapy resistant compared with other histologic subtypes. An inhibitor against the mammalian target of rapamycin, temsirolimus (TEM) has been reported to be effective in renal CCC. Therefore, we investigated the effects of TEM in patients with CCC of the ovary. Six patients with CCC of the ovary who had been heavily pretreated by more than 4 regimens were given TEM: the cycle consisted of weekly TEM (10 mg/m 2) for 3 weeks followed by 1 week off. The treatment was continued until development of either progressive disease, or unmanageable adverse effects. Response evaluation was based upon the Response Evaluation Criteria in Solid Tumors version 1.0. Adverse effects were analyzed according to Common Terminology Criteria for Adverse Events version 3.0. The median cycle of weekly TEM was 3 (range 2-14). Among five cases in which responses could be evaluated, partial response was observed in one case (20%) and stabilized disease was seen in another case (20%). There were no toxicities greater than grade 3, and no case developed severe toxicity requiring discontinuation of weekly TEM. The patient who showed a partial response obtained a progression-free period of 14 months. In conclusion, weekly TEM shows a potential therapeutic benefit for patients with CCC of the ovary. Further studies including a translational approach are needed to select candidates for whom TEM therapy would be beneficial.

Original languageEnglish
Pages (from-to)605-609
Number of pages5
JournalInternational Journal of Clinical Oncology
Volume16
Issue number5
DOIs
Publication statusPublished - 2011 Oct

Fingerprint

Ovary
Carcinoma
temsirolimus
Sirolimus
Renal Cell Carcinoma
Terminology
Therapeutics
Drug Therapy

Keywords

  • MTOR inhibitor
  • Ovarian clear cell carcinoma
  • Recurrence
  • Refractory
  • Temsirolimus

ASJC Scopus subject areas

  • Oncology
  • Surgery
  • Hematology
  • Medicine(all)

Cite this

Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary : A report of six cases. / Takano, Masashi; Kikuchi, Yoshihiro; Kudoh, Kazuya; Goto, Tomoko; Furuya, Kenichi; Kikuchi, Ryoko; Kita, Tsunekazu; Fujiwara, Keiichi; Shiozawa, Tanri; Aoki, Daisuke.

In: International Journal of Clinical Oncology, Vol. 16, No. 5, 10.2011, p. 605-609.

Research output: Contribution to journalArticle

Takano, Masashi ; Kikuchi, Yoshihiro ; Kudoh, Kazuya ; Goto, Tomoko ; Furuya, Kenichi ; Kikuchi, Ryoko ; Kita, Tsunekazu ; Fujiwara, Keiichi ; Shiozawa, Tanri ; Aoki, Daisuke. / Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary : A report of six cases. In: International Journal of Clinical Oncology. 2011 ; Vol. 16, No. 5. pp. 605-609.
@article{27ea3dddcf8a4de8805f3cacc477667f,
title = "Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: A report of six cases",
abstract = "Clear cell carcinoma (CCC) of the ovary is well-known to be chemotherapy resistant compared with other histologic subtypes. An inhibitor against the mammalian target of rapamycin, temsirolimus (TEM) has been reported to be effective in renal CCC. Therefore, we investigated the effects of TEM in patients with CCC of the ovary. Six patients with CCC of the ovary who had been heavily pretreated by more than 4 regimens were given TEM: the cycle consisted of weekly TEM (10 mg/m 2) for 3 weeks followed by 1 week off. The treatment was continued until development of either progressive disease, or unmanageable adverse effects. Response evaluation was based upon the Response Evaluation Criteria in Solid Tumors version 1.0. Adverse effects were analyzed according to Common Terminology Criteria for Adverse Events version 3.0. The median cycle of weekly TEM was 3 (range 2-14). Among five cases in which responses could be evaluated, partial response was observed in one case (20{\%}) and stabilized disease was seen in another case (20{\%}). There were no toxicities greater than grade 3, and no case developed severe toxicity requiring discontinuation of weekly TEM. The patient who showed a partial response obtained a progression-free period of 14 months. In conclusion, weekly TEM shows a potential therapeutic benefit for patients with CCC of the ovary. Further studies including a translational approach are needed to select candidates for whom TEM therapy would be beneficial.",
keywords = "MTOR inhibitor, Ovarian clear cell carcinoma, Recurrence, Refractory, Temsirolimus",
author = "Masashi Takano and Yoshihiro Kikuchi and Kazuya Kudoh and Tomoko Goto and Kenichi Furuya and Ryoko Kikuchi and Tsunekazu Kita and Keiichi Fujiwara and Tanri Shiozawa and Daisuke Aoki",
year = "2011",
month = "10",
doi = "10.1007/s10147-010-0177-z",
language = "English",
volume = "16",
pages = "605--609",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary

T2 - A report of six cases

AU - Takano, Masashi

AU - Kikuchi, Yoshihiro

AU - Kudoh, Kazuya

AU - Goto, Tomoko

AU - Furuya, Kenichi

AU - Kikuchi, Ryoko

AU - Kita, Tsunekazu

AU - Fujiwara, Keiichi

AU - Shiozawa, Tanri

AU - Aoki, Daisuke

PY - 2011/10

Y1 - 2011/10

N2 - Clear cell carcinoma (CCC) of the ovary is well-known to be chemotherapy resistant compared with other histologic subtypes. An inhibitor against the mammalian target of rapamycin, temsirolimus (TEM) has been reported to be effective in renal CCC. Therefore, we investigated the effects of TEM in patients with CCC of the ovary. Six patients with CCC of the ovary who had been heavily pretreated by more than 4 regimens were given TEM: the cycle consisted of weekly TEM (10 mg/m 2) for 3 weeks followed by 1 week off. The treatment was continued until development of either progressive disease, or unmanageable adverse effects. Response evaluation was based upon the Response Evaluation Criteria in Solid Tumors version 1.0. Adverse effects were analyzed according to Common Terminology Criteria for Adverse Events version 3.0. The median cycle of weekly TEM was 3 (range 2-14). Among five cases in which responses could be evaluated, partial response was observed in one case (20%) and stabilized disease was seen in another case (20%). There were no toxicities greater than grade 3, and no case developed severe toxicity requiring discontinuation of weekly TEM. The patient who showed a partial response obtained a progression-free period of 14 months. In conclusion, weekly TEM shows a potential therapeutic benefit for patients with CCC of the ovary. Further studies including a translational approach are needed to select candidates for whom TEM therapy would be beneficial.

AB - Clear cell carcinoma (CCC) of the ovary is well-known to be chemotherapy resistant compared with other histologic subtypes. An inhibitor against the mammalian target of rapamycin, temsirolimus (TEM) has been reported to be effective in renal CCC. Therefore, we investigated the effects of TEM in patients with CCC of the ovary. Six patients with CCC of the ovary who had been heavily pretreated by more than 4 regimens were given TEM: the cycle consisted of weekly TEM (10 mg/m 2) for 3 weeks followed by 1 week off. The treatment was continued until development of either progressive disease, or unmanageable adverse effects. Response evaluation was based upon the Response Evaluation Criteria in Solid Tumors version 1.0. Adverse effects were analyzed according to Common Terminology Criteria for Adverse Events version 3.0. The median cycle of weekly TEM was 3 (range 2-14). Among five cases in which responses could be evaluated, partial response was observed in one case (20%) and stabilized disease was seen in another case (20%). There were no toxicities greater than grade 3, and no case developed severe toxicity requiring discontinuation of weekly TEM. The patient who showed a partial response obtained a progression-free period of 14 months. In conclusion, weekly TEM shows a potential therapeutic benefit for patients with CCC of the ovary. Further studies including a translational approach are needed to select candidates for whom TEM therapy would be beneficial.

KW - MTOR inhibitor

KW - Ovarian clear cell carcinoma

KW - Recurrence

KW - Refractory

KW - Temsirolimus

UR - http://www.scopus.com/inward/record.url?scp=84857081287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857081287&partnerID=8YFLogxK

U2 - 10.1007/s10147-010-0177-z

DO - 10.1007/s10147-010-0177-z

M3 - Article

VL - 16

SP - 605

EP - 609

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 5

ER -